ArticleDrug development research2013
Anti-Oligomannose Antibodies as Potential Serum Biomarkers of Aggressive Prostate Cancer.
Article in Drug development research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Exploring Glycan Markers for Immunotyping and Precision-targeting of Breast Circulating Tumor Cells.Archives of medical research · 2015Trial
- Probing the Broad-Spectrum Virus-Neutralizing Epitopes Using the High-Density Oligomannose-Conjugates and Carbohydrate Microarrays.Bioconjugate chemistry · 2025Article
- Hypoxia-Induced Adaptations of N-Glycomes and Proteomes in Breast Cancer Cells and Their Secreted Extracellular Vesicles.International journal of molecular sciences · 2024Article
- Serum antibody screening using glycan arrays.Chemical Society reviews · 2024Review
- Rewiring of the N-Glycome with prostate cancer progression and therapy resistance.NPJ precision oncology · 2023Article
- Assessment of Immunologically Potent Carbohydrates.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Article
- Associations Between Genetically Predicted Plasma N-Glycans and Prostate Cancer Risk: Analysis of Over 140,000 European Descendants.Pharmacogenomics and personalized medicine · 2021Article
- Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma.Cell reports · 2020Article
- Recent Progress in Chemo-Enzymatic Methods for the Synthesis of N-Glycans.Frontiers in chemistry · 2020Review
- Coronaviruses' sugar shields as vaccine candidates.Current trends in immunology · 2020Article
- Glycans as Biomarkers in Prostate Cancer.International journal of molecular sciences · 2019Review
- Top-Down Chemoenzymatic Approach to Synthesizing Diverse High-Mannose N-Glycans and Related Neoglycoproteins for Carbohydrate Microarray Analysis.Bioconjugate chemistry · 2018Article
- MALDI Mass Spectrometry Imaging of N-Linked Glycans in Cancer Tissues.Advances in cancer research · 2017Review
- The role of glycans in the development and progression of prostate cancer.Nature reviews. Urology · 2016Review
- Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability.EBioMedicine · 2016Article
- Targeting N-glycan cryptic sugar moieties for broad-spectrum virus neutralization: progress in identifying conserved molecular targets in viruses of distinct phylogenetic origins.Molecules (Basel, Switzerland) · 2015Article
- Carbohydrate Microarrays Identify Blood Group Precursor Cryptic Epitopes as Potential Immunological Targets of Breast Cancer.Journal of immunology research · 2015Article
- Uncovering cryptic glycan markers in multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE).Drug development research · 2014Article
- Glyco-epitope Diversity: An Evolving Area of Glycomics Research and Biomarker Discovery.Journal of proteomics & bioinformatics · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
Abstract
[Table: see text] This study bridges a carbohydrate microarray discovery and a large-scale serological validation of anti-oligomannose antibodies as novel serum biomarkers of aggressive prostate cancer (PCa). Experimentally, a Man9-cluster-specific enzyme-linked immunosorbent assay was established to enable sensitive detection of anti-Man9 antibodies in human sera. A large-cohort of men with PCa or benign prostatic hyperplasia (BPH) whose sera were banked at Stanford University was characterized using this assay. Subjects included patients with 100% Gleason grade 3 cancer (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.